Iressa Gets Support in Asia Privacy Policy | Contact |

Iressa Gets Support in Asia

BBBOnLine Reliability Seal

Home - Health Insurance - Health Insurance Resources - More Resources - Iressa Gets Support in Asia

Find Local Doctors & Health Plans : Enter Your ...

ZIP Code

Quotes Type

Your E-mail ID

[Optional and Compliant to Federal Laws]

Iressa Gets Support in Asia

Iressa Gets Support in Asia

Although, U.S. government imposed ban on the lung cancer pill, Iressa, but 4 years after that prohibition it gets support in Asia. A research has shown that it has capability to slow down the effects of this fatal disease in some lung cancer patients; better than conventional chemotherapy.

The study has revealed that it can be considered as first-line treatment since it is more effectual than standard chemotherapy. Some experts are hopeful that the study result would encourage Food and Drug Administration to allow wide usage of this drug, manufactured by AstraZeneca PLC. However, others are uncertain.

Although, the research reveals the positive effect of Iressa on cancer treatment over one year, but its long-term effect is still doubtful.

The study was also conducted in Asia and it seems to perform the best with certain patients - women, Asians and non-smokers who carry specific gene mutation.

Dr. Len Lichtenfeld, the deputy chief medical officer at the American Cancer Society said that he would venture saying that the additional researches will be asked in the American population.

AstraZeneca that sponsored the research is however not planning a new manipulation for extended FDA approval of this medicine, as said by an AstraZeneca spokesperson. However, she mentioned that the company is continuously sharing information about the medicine with the federal medical officials.

Iressa should be consumed on daily basis. It specifically targets the cancer cells than healthy cells. It is definitely an attractive and effective alternative to traditional chemotherapy.

In the year 2003, the Food and Drug Administration (FDA) admitted Iressa as the last-resort therapy for the patients with the common type of lung cancer also known as non-small-cell lung cancer.

The situation was noteworthy: more Americans die by lung cancer than any other type of tumor. The Cancer Society evaluates that lung cancer may cause about 165,000 U.S. deaths in the current year. 85% of the lung cancer patients are suffering from non-small-cell lung cancer.

Iressa Gets Support in Asia  Get Your Free Medical Insurance Quotes Now!

Home     Contact Us     Privacy Policy     Our Edge     Disclaimer     Site Map     More Resources

Copyright 2003-2021 Group, Inc. [Protected under U.S. Copyright TX5-874-987 & Several Pending Patents]

Page copy protected against web site content infringement by Copyscape.